Dr. McIntyre on Frontline Eribulin in HER2-Negative MBC
Kristi McIntyre, MD, from Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
Kristi McIntyre, MD, a physician with Texas Oncology, discusses the results of a phase II, multicenter, single-arm study that studies eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer.
McIntyre says the overall response rate (ORR) of the trial was 29% but the clinical benefit rate, which was CR, PR and stable disease, was 52%.
Eribulin is a non-taxane, McIntyre explains, but it also targets the microtubule as a taxane would. Eribulin is given IV on day 1 and 8 of a 28-day cycle. McIntyre says the treatment lasts only 2-5 minutes and does not have hypersensitivity reactions like taxanes.
This treatment, McIntyre says, compares favorably to other first-line agents in metastatic breast cancer. The study contained both triple-negative and hormone positive breast cancer patients and all of the metastatic breast cancer patients that participated were HER2-negative.
<<<
